Gilead Foundation Awards Over $3 Million to Support People Living With Metastatic Breast Cancer
Gilead Sciences, Inc. (GILD)
Last gilead sciences, inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.gilead.com
Company Research
Source: Business Wire
– Funding Empowers 53 Organizations to Enhance Education, Care and Support Services – FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Foundation today announced a commitment of more than $3 million in new grants to help address critical gaps in education, care delivery and support services for people affected by metastatic breast cancer (mBC). Building on more than $21 million in support since 2021, funding distributed through the Gilead Foundation advances efforts to improve access to breast cancer education and care nationwide, complementing Gilead Sciences’ broader commitment to creating sustainable change for the breast cancer community.Breast cancer is one of the most common cancers affecting women in the United States, with an estimated 168,000 people impacted by disease that has spread to other parts of the body (metastatic disease). While treatment options have advanced significantly, the five-year relative survival rate for people with mBC is 29%, highlighting an urgent need
Show less
Read more
Impact Snapshot
Event Time:
GILD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GILD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GILD alerts
High impacting Gilead Sciences, Inc. news events
Weekly update
A roundup of the hottest topics
GILD
News
- Gilead Sciences (NASDAQ:GILD) had its price target raised by analysts at Morgan Stanley from $147.00 to $151.00. They now have an "overweight" rating on the stock.MarketBeat
- Cantor Fitzgerald Maintains a Buy Rating on Gilead Sciences (GILD) [Yahoo! Finance]Yahoo! Finance
- Gilead Sciences (NASDAQ:GILD) had its price target raised by analysts at HSBC Holdings plc from $110.00 to $133.00. They now have a "hold" rating on the stock.MarketBeat
- Gilead Sciences (NASDAQ:GILD) had its price target raised by analysts at Wells Fargo & Company from $145.00 to $150.00. They now have an "overweight" rating on the stock.MarketBeat
- Gilead Sciences (NASDAQ:GILD) was upgraded by analysts at UBS Group AG to a "hold" rating.MarketBeat
GILD
Earnings
- 10/30/25 - Beat
GILD
Sec Filings
- 12/11/25 - Form 4
- 12/11/25 - Form 4
- 12/11/25 - Form 4
- GILD's page on the SEC website